Privia Health Group, Inc. (NASDAQ:PRVA) Shares Acquired by Bellevue Group AG

Bellevue Group AG lifted its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 0.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,059,171 shares of the company’s stock after purchasing an additional 7,475 shares during the quarter. Bellevue Group AG owned 0.89% of Privia Health Group worth $20,749,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PRVA. Vanguard Group Inc. grew its stake in Privia Health Group by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 11,400,035 shares of the company’s stock valued at $223,327,000 after acquiring an additional 121,701 shares during the period. Riverbridge Partners LLC grew its stake in Privia Health Group by 17.5% in the 1st quarter. Riverbridge Partners LLC now owns 5,399,662 shares of the company’s stock valued at $105,779,000 after acquiring an additional 804,304 shares during the period. Norges Bank acquired a new stake in Privia Health Group in the 4th quarter valued at $27,959,000. Charles Schwab Investment Management Inc. grew its stake in Privia Health Group by 3.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 852,591 shares of the company’s stock valued at $19,635,000 after acquiring an additional 29,835 shares during the period. Finally, WCM Investment Management LLC grew its stake in Privia Health Group by 4.3% in the 1st quarter. WCM Investment Management LLC now owns 572,454 shares of the company’s stock valued at $11,214,000 after acquiring an additional 23,367 shares during the period. Institutional investors and hedge funds own 94.48% of the company’s stock.

Insider Transactions at Privia Health Group

In other news, Director Adam Boehler purchased 277,565 shares of the business’s stock in a transaction dated Tuesday, May 21st. The stock was acquired at an average price of $16.17 per share, for a total transaction of $4,488,226.05. Following the acquisition, the director now directly owns 5,488,701 shares of the company’s stock, valued at $88,752,295.17. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Thomas Bartrum sold 2,252 shares of Privia Health Group stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total value of $41,481.84. Following the completion of the sale, the executive vice president now owns 103,862 shares in the company, valued at approximately $1,913,138.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Adam Boehler bought 277,565 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was bought at an average price of $16.17 per share, with a total value of $4,488,226.05. Following the acquisition, the director now directly owns 5,488,701 shares in the company, valued at approximately $88,752,295.17. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 293,235 shares of company stock worth $4,745,481 and sold 45,457 shares worth $827,810. Insiders own 14.20% of the company’s stock.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA traded up $0.47 during midday trading on Friday, reaching $20.46. 423,617 shares of the stock were exchanged, compared to its average volume of 693,804. The company has a 50 day simple moving average of $17.55 and a 200 day simple moving average of $19.09. The stock has a market capitalization of $2.44 billion, a P/E ratio of 136.40, a PEG ratio of 3.21 and a beta of 0.78. Privia Health Group, Inc. has a twelve month low of $15.92 and a twelve month high of $28.10.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.03). The firm had revenue of $415.24 million for the quarter, compared to analyst estimates of $435.07 million. Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. On average, research analysts expect that Privia Health Group, Inc. will post 0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on PRVA. Robert W. Baird began coverage on shares of Privia Health Group in a research note on Thursday, May 30th. They issued an “outperform” rating and a $23.00 price target on the stock. Stifel Nicolaus lowered their target price on shares of Privia Health Group from $28.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Canaccord Genuity Group reduced their target price on shares of Privia Health Group from $37.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Truist Financial lowered their price target on shares of Privia Health Group from $28.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, May 15th. Finally, Barclays cut their price objective on shares of Privia Health Group from $22.00 to $19.00 and set an “equal weight” rating for the company in a report on Monday, May 20th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.54.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.